Table 1:
Cases about checkpoint inhibitor use after allogenic stem cell transplantation.
| Author Year | CPI | Dose (mg/kg) |
Primary disease (n) | Response (n) |
GVHD (grade) |
Other Outcomes (n) |
|---|---|---|---|---|---|---|
| Onizukaet al. 2016 | NV | 0.5–2 | HL (1) | PR (1) | GVHD worsened | NA |
| Angenendtet al. 2016 | NV | 3 | HL (1) | CR (1) | none | NA |
| Villasboaset al. 2016 | PZ | 2 | HL (2) | CR (1) PR (1) |
none | NA |
| Chan et al. 2016 | PZ | 2 | ALCL (1) | PR (1) | none | NA |
| Yaredet al. 2016 | NV | 0.5–3 | HL (1) | PR (1) | none | Pneumonitis, Hepatitis |
| Shad et al. 2016 | NV | 3 | HL (1) | CR (1) | none | NA |
| Albringet al. 2017 | NVa | AML (3) | CR (1) SD (1) PD (1) |
GVHD (2)* | Myalgias | |
| Singh et al. 2017 | PZ | NA | HL (1) | CR (1) | GVHD (4) | Death = pneumonia |
| Kwonget al. 2017 | PZ | 2 | NK/T cell Lymphoma (7) |
CR (5) PR (1) |
GVHD (2) * | NA |
| Godfrey et al. 2017 | NV | 3 | HL (3) | PR (3) | none | Arthralgias, Conjunctivitis and Rash (2) |
| Cheikhet al. 2017 | NV | 3 | HL (2) | CR (2) | GVHD (3)* | Death = fungal infection (1) |
| Boekstegerset al. 2017 | PZ | 3.3 | ALL (1) | CR | GVHD (4) | Death |
| Covutet al. 2017 | NV | NA | HL (2) | CR | none | Death = hepatic failure |
*
only one patient had GVHD
a
1 patient received single dose of 100 mg; 1 received a repetitive regimen of 0.3–1mg/kg weekly for 5 infusions;1 received two injections (100 mg each)
Abbreviations: AML= acute myeloid leukemia, ALL= acute lymphocytic lymphoma, ALCL= anaplastic large cell lymphoma, CPI= checkpoint inhibitor, CR= complete remission, GVHD= graft versus host disease, HL= classical Hodgkin’s lymphoma, n= number of patients, NV= nivolumab, PD= progressed disease, PR= partial remission, PZ= pembrolizumab, SD= stable disease, NK: Natural killer, NA: Not available.